ES2716800T3 - Métodos y composiciones para vacunar contra Staphylococcus aureusaureus - Google Patents

Métodos y composiciones para vacunar contra Staphylococcus aureusaureus Download PDF

Info

Publication number
ES2716800T3
ES2716800T3 ES12817530T ES12817530T ES2716800T3 ES 2716800 T3 ES2716800 T3 ES 2716800T3 ES 12817530 T ES12817530 T ES 12817530T ES 12817530 T ES12817530 T ES 12817530T ES 2716800 T3 ES2716800 T3 ES 2716800T3
Authority
ES
Spain
Prior art keywords
vaccine
staphylococcus aureus
use according
ndv
mrsa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12817530T
Other languages
English (en)
Spanish (es)
Inventor
Michael Yeaman
John Edwards
Scott Filler
Ashraf Ibrahim
Yue Fu
John Hennessey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novadigm Therapeutics Inc
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Original Assignee
Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Novadigm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center, Novadigm Therapeutics Inc filed Critical Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Application granted granted Critical
Publication of ES2716800T3 publication Critical patent/ES2716800T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES12817530T 2011-07-22 2012-07-20 Métodos y composiciones para vacunar contra Staphylococcus aureusaureus Active ES2716800T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510896P 2011-07-22 2011-07-22
PCT/US2012/000328 WO2013015831A1 (en) 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus

Publications (1)

Publication Number Publication Date
ES2716800T3 true ES2716800T3 (es) 2019-06-17

Family

ID=47601425

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12817530T Active ES2716800T3 (es) 2011-07-22 2012-07-20 Métodos y composiciones para vacunar contra Staphylococcus aureusaureus

Country Status (12)

Country Link
US (1) US10653757B2 (enExample)
EP (1) EP2734229B1 (enExample)
JP (1) JP2014521605A (enExample)
CN (1) CN103998056B (enExample)
AU (1) AU2012287513A1 (enExample)
BR (1) BR112014001409A2 (enExample)
CA (1) CA2842626A1 (enExample)
EA (1) EA035513B1 (enExample)
ES (1) ES2716800T3 (enExample)
GE (1) GEP201706766B (enExample)
UA (1) UA114286C2 (enExample)
WO (1) WO2013015831A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
WO2014153241A1 (en) 2013-03-14 2014-09-25 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
HK1220389A1 (zh) * 2013-03-14 2017-05-05 Wang Rongfu 调控调节性t细胞功能的方法和组合物
BR112015022963A8 (pt) * 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
WO2017155949A1 (en) * 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN105713096B (zh) * 2016-03-29 2019-01-01 黑龙江八一农垦大学 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
JP7439371B2 (ja) 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
KR20260052081A (ko) * 2023-08-09 2026-04-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 단백질
WO2025240443A1 (en) * 2024-05-14 2025-11-20 University Of Rochester Candida for use in prevention or mitigation of cutaneous viral infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
JPH09500013A (ja) 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
CA2486618C (en) 2002-05-21 2013-04-09 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and uses thereof
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
BRPI0416205A (pt) * 2003-11-21 2006-12-26 Pfizer Prod Inc uso de antibióticos como adjuvantes de vacina
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
WO2007123850A2 (en) 2006-04-17 2007-11-01 Schering-Plough Ltd. Recombinant attenuated clostridium organisms and vaccine
WO2008147847A1 (en) 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
EP2296698A1 (en) 2008-05-29 2011-03-23 Intervet International BV Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
AU2010264538B2 (en) * 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
ES2606555T3 (es) 2009-07-03 2017-03-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center HYR1 como objetivo para la inmunización activa y pasiva contra Candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Also Published As

Publication number Publication date
CA2842626A1 (en) 2013-01-31
US10653757B2 (en) 2020-05-19
US20150273031A1 (en) 2015-10-01
EP2734229A1 (en) 2014-05-28
EA201391200A1 (ru) 2014-05-30
JP2014521605A (ja) 2014-08-28
BR112014001409A2 (pt) 2017-07-11
UA114286C2 (uk) 2017-05-25
AU2012287513A1 (en) 2014-03-13
EA035513B1 (ru) 2020-06-29
CN103998056B (zh) 2017-09-12
EP2734229B1 (en) 2019-01-02
CN103998056A (zh) 2014-08-20
AU2012287513A8 (en) 2014-06-19
GEP201706766B (en) 2017-10-25
WO2013015831A1 (en) 2013-01-31
EP2734229A4 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
US10653757B2 (en) Methods and compositions for vaccinating against Staphylococcus aureus
US20230338515A1 (en) Vaccines against coronavirus and methods of use
JP6655549B2 (ja) 免疫応答を誘導するための新規方法
EP2968497B1 (en) Compositions and methods for treating fungal and bacterial pathogens
US20230143215A1 (en) Immunization against sars-cov-related diseases
JP2019507759A (ja) 外陰部膣カンジダ症の予防及び治療で使用するための方法及びキット
EA025831B1 (ru) Композиции из hyr1-производных и способы лечения ими
US20240115693A1 (en) Sars-cov-2 antigen nanoparticles and uses there of
JP2017513849A (ja) Ａ群レンサ球菌ワクチン
US10258683B2 (en) Engineered vesicles comprising antigenic peptides and the uses thereof as modulators of immune responses
WO2022051866A1 (en) Vaccine for viral pathogens
US20240148864A1 (en) Polysaccharide adjuvants for virus vaccines
WO2014144222A2 (en) Compositions and methods of treating fungal and bacterial pathogens
KR20190039022A (ko) 샤가스 항원 및 항체, 및 이들의 조성물, 방법 및 용도
WO2019202285A1 (en) Pharmaceutical compositions and associated kits and uses
US11911459B2 (en) Nant COVID vaccine cross reactivity
US20250332246A1 (en) Enhanced expression via autotransporters
US20220218806A1 (en) Peptides and conjugates for treatment of arthritis
WO2023211281A1 (en) Antiviral vaccine composition
Smith et al. Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect
Sedaghat et al. Determination of bactericidal activity of serum against Vibrio cholerae outer membrane vesicles in BALB/c mice